November 13, 2019
Ono Pharmaceutical and Bristol-Myers Squibb on November 12 filed in Japan the combination therapy of their anti-PD-1 antibody Opdivo (nivolumab) and anti-CTLA-4 antibody Yervoy (ipilimumab) for an additional indication of microsatellite instability high (MSI-H) unresectable advanced or recurrent colorectal cancer...read more